At Hemostemix, we are relentlessly focused on developing effective and safe regenerative medicine that create new therapeutic options, treatment protocols and hope for millions of patients globally.
Our proprietary ACP-01 autologous (patient’s own) therapy, has been extensively studied in multiple clinical trials for Angina, Ischemic and Dilated Cardiomyopathy, Peripheral Arterial Disease (PAD) and Chronic Limb Threatening Ischemia (CLI).
Unlike fetal stem cells, autologous cells are collected from the patient's own body.
Low Patient Burden
Collection is via standard blood draw
No anesthesia
Avoids bone marrow harvest complications
Implant is via local injection
Risk Reduction
No tainted blood or blood products
Avoids immune rejection and graft-versus host disease (GVHD)
No risk of neoplasia (abnormal, new, uncontrolled cell growth) from pluripotent cells (cells that can develop into many different types of cells or tissue)
How ACP-01 Works
A Unique Mechanism of Action
FIND: ACP-01 migrates to areas of decreased blood flow (Ischemia)
EMBED: ACP-01 embeds into injured tissues and repopulates injured tissue
RELEASE: ACP--01 releases growth factors and reduces inflammation
GENERATE: ACP-01 generates new blood vessles to improve blood flow
Research Spotlight
Read this informative study demonstrating the efficacy and safety of ACP-O1 (VesCELL) in select patients with no option Critical Limb Ischemia. Key points highlighted in this paper include :
